Infectious Diseases COVID-19 HIV/AIDS Guillain-Barré Syndrome Chronic Diseases Vector-Borne Diseases Cancer Treatment Cancer Management Vaccines Neurodegenerative Conditions Acute Encephalitis Syndrome Encephalitis Chronic Wasting Disease Epidemic Response Dengue Overcrowding Risks Respiratory Illnesses Neurodegenerative Diseases Respiratory Issues Foot and Mouth Disease Vaccination Hansen's Disease Chronic Illness Guillain-Barre Syndrome Chronic Disease Funding Allocation Primary Amoebic Meningoencephalitis Sickle Cell Anaemia Asthma Management Heart Disease Chronic Conditions Influenza Flu Diagnosis HIV Awareness Bleeding Disorders Patient Care Healthcare Professionals Treatment Protocols Cardiovascular Health Liver Diseases Cognitive Decline HIV Epidemiological Studies Q-fever Health Recovery Protocols Avian Influenza Winter Illnesses Diarrhoea Flu Season Cancer Sickle Cell Disease Viral Hemorrhagic Fevers Stroke Covid-19 Infection Control Snakebite Treatment Thalassemia Health Alerts Heart Failure Alzheimer's Treatment Notifiable Diseases Avian Diseases Mortality Analysis Post-Viral Syndromes Vector Control Osteoarthritis
Data suggesting that lowering tau can slow Alzheimer’s progression have prompted Biogen to plan a pivotal Phase 3 in 2027.
